Literature DB >> 16127964

Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.

Robert B Zipursky1, Bruce K Christensen, Zafiris Daskalakis, Irvin Epstein, Paul Roy, Ivana Furimsky, Todd Sanger, Shitij Kapur.   

Abstract

OBJECTIVE: Response to typical antipsychotic medication has been associated with achieving a level of striatal dopamine D2 receptor occupancy in the range of 65% to 70%. We undertook this study to determine whether response to the atypical antipsychotic olanzapine occurs at lower levels of D2 receptor occupancy.
METHOD: Eighteen patients who presented with a first episode of psychosis were randomized to receive olanzapine 5 mg daily or haloperidol 2 mg daily in a double-blind design. We acquired positron emission tomography (PET) scans using the D2 ligand [11C]raclopride within the first 15 days of treatment to determine the percentage of D2 receptors occupied by the medication. According to response, dosage was then adjusted to a maximum dosage of 20 mg daily of either drug. PET scans were repeated after 10 to 12 weeks of treatment.
RESULTS: At the first PET scan, the 8 olanzapine-treated patients had significantly lower D2 receptor occupancies (mean 63.4%, SD 7.3) than those observed in the 10 patients treated with haloperidol (mean 73.0%, SD 6.1). When patients were rescanned following dosage adjustment, mean D2 receptor occupancies were greater than 70% in both groups. D2 receptor occupancies did not differ significantly between the olanzapine-treated group (mean 72.0%, SD 5.7) and the haloperidol-treated group (mean 78.7%, SD 7.6).
CONCLUSIONS: These results suggest that, in patients being treated for a first episode of psychosis, olanzapine has its antipsychotic effect at approximately the same levels of D2 receptor occupancy as are achieved with low dosages of haloperidol.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127964     DOI: 10.1177/070674370505000806

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  6 in total

Review 1.  Olanzapine: in adolescents with schizophrenia or bipolar I disorder.

Authors:  Paul L McCormack
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

2.  Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients.

Authors:  G J E Schmitt; S Dresel; T Frodl; C la Fougère; R Boerner; K Hahn; H-J Möller; E M Meisenzahl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-13       Impact factor: 5.270

3.  Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission.

Authors:  Monica M Marcus; Kent Jardemark; Anna Malmerfelt; Carl Björkholm; Torgny H Svensson
Journal:  Neuropsychopharmacology       Date:  2010-05-12       Impact factor: 7.853

Review 4.  Cure therapeutics and strategic prevention: raising the bar for mental health research.

Authors:  T R Insel; E M Scolnick
Journal:  Mol Psychiatry       Date:  2006-01       Impact factor: 15.992

5.  Stimulant Therapy in Acute Traumatic Brain Injury: Prescribing Patterns and Adverse Event Rates at 2 Level 1 Trauma Centers.

Authors:  Megan E Barra; Saef Izzy; Aliyah Sarro-Schwartz; Ronald E Hirschberg; Nicole Mazwi; Brian L Edlow
Journal:  J Intensive Care Med       Date:  2019-04-09       Impact factor: 3.510

6.  Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse.

Authors:  Athan Spiros; Robert Carr; Hugo Geerts
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.